Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety-Reference-Cited by-同舟云学术

Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety

Published:2024-09-01 Issue: Volume: Page:
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Kandeel Mahmoud^ORCID,Morsy Mohamed A.,Alkhodair Khalid M.,Alhojaily Sameer

Funder

King Salman Center for Disability Research

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10787-024-01563-3.pdf

Reference34 articles.

1. Benjamin O, Goyal A, Lappin SL (2018) Disease modifying anti-rheumatic drugs (DMARD). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK507863/. Updated 3 July 2023

2. Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A (2024a) Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open 10(2):e003912. https://doi.org/10.1136/rmdopen-2023-003912

3. Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee S-H, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R (2020) Live Zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb/IV randomized study. Arthritis Care Res (Hoboken) 72(3):353–359. https://doi.org/10.1002/acr.24010

4. Choi SR, Shin A, Ha Y-J, Lee YJ, Lee EB, Kang EH (2023) Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 25(1):129. https://doi.org/10.1186/s13075-023-03111-w

5. Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304–311. https://doi.org/10.1136/annrheumdis-2020-218510